Effect of herpes zoster vaccine on patients after hematopoietic stem cell transplantation: a systematic review and meta-analysis.

IF 4 3区医学 Q2 VIROLOGY

Virology Journal Pub Date : 2025-03-02 DOI:10.1186/s12985-025-02670-5

Xunyi Jiao, Jinli Zhu, Yangyang Ding, Meng Xiao, Zhimin Zhai

{"title":"Effect of herpes zoster vaccine on patients after hematopoietic stem cell transplantation: a systematic review and meta-analysis.","authors":"Xunyi Jiao, Jinli Zhu, Yangyang Ding, Meng Xiao, Zhimin Zhai","doi":"10.1186/s12985-025-02670-5","DOIUrl":null,"url":null,"abstract":"Background: Herpes zoster(HZ), a severe complication following hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. The effect of herpes zoster vaccine(HZV) for preventing HZ on patients after HSCT is unclear. We conducted a systematic review and meta-analysis investigating the efficacy and safety of HZV in HSCT recipients.Methods: The databases Pubmed, Embase, and Cochrane Library were searched to identify relevant studies. Random-effects models were used to calculate risk ratios (RRs) and 95% confidence intervals (CIs) for HZ infection and related events.Results: A total of 3048 individuals from five studies (four randomized controlled trials and one retrospective cohort study) were included. The overall incidence of HZ in the HZV group and control group was 6.4% and 18.3% respectively, resulting in a pooled RR of 0.36 (95%CI, 0.29-0.45; P < 0.001), indicating no heterogeneity (P = 0.88,I2 = 0). HZV demonstrated a reduction in the risk of PHN (RR, 0.40; 95% CI, 0.15-1.11), although statistical significance was not reached (P = 0.08). Furthermore, through two independent RCTs, HZV showed a decrease in the incidence of HZ-related complications compared to placebo administration. The overall incidence of adverse events in the HZV group and control group was found to be 63.6% and 60.2% respectively, with a pooled RR of 1.02 (95% CI, 0.97-1.06, P = 0.51), indicating no heterogeneity (P = 0.66, I2 = 0).Conclusion: The HZV group demonstrated a significant reduction in the risk of HZ among HSCT recipients, without an increase in adverse events. This highlights the positive impact of HZV on decreasing the incidence of PHN and complications associated with HZ. Furthermore, our findings support the effectiveness and tolerability of HZV as a preventive measure against HZ for HSCT recipients.","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"22 1","pages":"54"},"PeriodicalIF":4.0000,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874116/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12985-025-02670-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Herpes zoster(HZ), a severe complication following hematopoietic stem cell transplantation (HSCT), is associated with significant morbidity. The effect of herpes zoster vaccine(HZV) for preventing HZ on patients after HSCT is unclear. We conducted a systematic review and meta-analysis investigating the efficacy and safety of HZV in HSCT recipients.

Methods: The databases Pubmed, Embase, and Cochrane Library were searched to identify relevant studies. Random-effects models were used to calculate risk ratios (RRs) and 95% confidence intervals (CIs) for HZ infection and related events.

Results: A total of 3048 individuals from five studies (four randomized controlled trials and one retrospective cohort study) were included. The overall incidence of HZ in the HZV group and control group was 6.4% and 18.3% respectively, resulting in a pooled RR of 0.36 (95%CI, 0.29-0.45; P < 0.001), indicating no heterogeneity (P = 0.88,I² = 0). HZV demonstrated a reduction in the risk of PHN (RR, 0.40; 95% CI, 0.15-1.11), although statistical significance was not reached (P = 0.08). Furthermore, through two independent RCTs, HZV showed a decrease in the incidence of HZ-related complications compared to placebo administration. The overall incidence of adverse events in the HZV group and control group was found to be 63.6% and 60.2% respectively, with a pooled RR of 1.02 (95% CI, 0.97-1.06, P = 0.51), indicating no heterogeneity (P = 0.66, I² = 0).

Conclusion: The HZV group demonstrated a significant reduction in the risk of HZ among HSCT recipients, without an increase in adverse events. This highlights the positive impact of HZV on decreasing the incidence of PHN and complications associated with HZ. Furthermore, our findings support the effectiveness and tolerability of HZV as a preventive measure against HZ for HSCT recipients.

查看原文本刊更多论文

带状疱疹疫苗对造血干细胞移植后患者的影响：系统回顾和荟萃分析。

背景：带状疱疹（HZ）是造血干细胞移植（HSCT）后的一种严重并发症，发病率高。带状疱疹疫苗（HZV）对HSCT后患者预防HZ的作用尚不清楚。我们进行了一项系统综述和荟萃分析，调查HZV在HSCT受者中的有效性和安全性。方法：检索Pubmed、Embase和Cochrane Library数据库，确定相关研究。随机效应模型用于计算HZ感染及相关事件的风险比（rr）和95%置信区间（ci）。结果：共纳入5项研究（4项随机对照试验和1项回顾性队列研究）的3048例个体。HZV组和对照组的总HZ发病率分别为6.4%和18.3%，合并RR为0.36 (95%CI, 0.29-0.45；p 2 = 0)。HZV显示PHN风险降低(RR, 0.40；95% CI, 0.15-1.11)，但未达到统计学意义（P = 0.08）。此外，通过两项独立的随机对照试验，与安慰剂相比，HZV显示HZV相关并发症的发生率降低。HZV组和对照组的不良事件总发生率分别为63.6%和60.2%，合并RR为1.02 (95% CI, 0.97-1.06, P = 0.51)，无异质性（P = 0.66, I2 = 0）。结论：HZV组在HSCT受者中显示出HZ风险的显著降低，而不良事件没有增加。这突出了HZV对降低PHN发生率和与HZ相关的并发症的积极影响。此外，我们的研究结果支持HZV作为HSCT受者预防HZ的有效性和耐受性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Virology Journal 医学-病毒学

CiteScore

7.40

自引率

2.10%

发文量

186

审稿时长

1 months

期刊介绍： Virology Journal is an open access, peer reviewed journal that considers articles on all aspects of virology, including research on the viruses of animals, plants and microbes. The journal welcomes basic research as well as pre-clinical and clinical studies of novel diagnostic tools, vaccines and anti-viral therapies. The Editorial policy of Virology Journal is to publish all research which is assessed by peer reviewers to be a coherent and sound addition to the scientific literature, and puts less emphasis on interest levels or perceived impact.